Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CAR T - Cell Therapy - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
This report offers a comprehensive overview of the CAR T-Cell Therapy landscape, covering insights from over 250 companies and 500 drugs. It evaluates therapeutics by product type, stage, route of administration, and molecule type, and highlights inactive pipeline products globally.
CAR T-cells fuse proteins from monoclonal antibodies and T-cell receptor domains, incorporating antigen-binding domains from antibody variable domains, TCR chain signaling domains, and additional costimulatory domains. Since their inception in 1989, CAR T-cells have evolved through four generations, each enhancing therapeutic efficiency and production capabilities.
The rapid generation of tumor-specific T-cells, minimal autoimmunity risk, and active engagement in both CD4+ and CD8+ T-cells underscore CAR T-cells' advantages. However, the emergence of tumor resistance to a single antigen and expression overlap between tumor and normal tissues pose challenges, particularly for solid tumors.
Industry Analysis
CAR T-Cell Therapy continues to witness significant collaboration and commercialization efforts across the industry. Key players including Kite Pharma, Bristol Myers Squibb, and JW Therapeutics are at the forefront, with pioneering therapies like KTE-X19, Abecma, and Relmacabtagene autoleucel.
Kite Pharma received EU and US approvals for Tecartus (KTE-X19). Bristol Myers Squibb advances Abecma, a therapy pioneering BCMA targeting for multiple myeloma, across the EU and US markets. JW Therapeutics leads in China with Relmacabtagene autoleucel, the first Category 1 biologics-approved CAR-T product, serving significant unmet needs in cancer treatment.
Pipeline Therapies and Market Outlook
CAR T-Cell Therapy is expanding its pipeline with innovations by companies like CARsgen, Cartesian Therapeutics, and Autolus Therapeutics. Focused efforts on hematologic and solid tumors reflect optimism for reshaping treatment paradigms. Notable pipeline products include zevorcabtagene autoleucel, Descartes-11, and AUTO8.
CARsgen is advancing zevor-cel for multiple myeloma treatment, while Cartesian's Descartes-11 aims for mRNA-engineered CARs with therapeutic precision. Autolus's AUTO8, targeting BCMA and CD19, promises enhanced efficacy for multiple myeloma.
Conclusion
With robust collaborations and groundbreaking therapies, the CAR T-Cell Therapy landscape is poised for transformative cancer treatment solutions. The ongoing advancements invite further innovation in targeting precision and overcoming current therapeutic limitations, setting the stage for a thriving future in global cancer care.
Key Topics Covered:
Introduction
Executive Summary
CAR T - Cell Therapy: Overview
- Introduction
- Mechanism of Action
- Application
- Limitation
- Approved Therapies
CAR T - Cell Therapy-Analytical Perspective: In-depth Commercial Assessment
- CAR T - Cell Therapy Collaboration Analysis by Companies
Competitive Landscape
- Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
CAR T - Cell Therapy: Company and Product Profiles (Marketed Therapies)
JW Therapeutics
- Company Overview
Relmacabtagene autoleucel
- Product Description
- Research and Development Activities
- Product Developmental Activities
Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Registered)
- Comparative Analysis
CARsgen
- Company Overview
Zevorcabtagene autoleucel
- Product Description
- Research and Development Activities
- Product Developmental Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Cartesian Therapeutics
- Company Overview
Descartes 011
- Product Description
- Research and Development Activities
- Product Developmental Activities
Early Stage Products (Phase I)
- Comparative Analysis
Autolus Therapeutics
- Company Overview
AUTO-8
- Product Description
- Research and Development Activities
- Product Developmental Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Sana Biotechnology
- Company Overview
SG299
- Product Description
- Research and Development Activities
- Product Developmental Activities
Inactive Products
- Comparative Analysis
CAR T - Cell Therapy - Unmet needs
CAR T - Cell Therapy- Market drivers and barriers
Companies Featured
- Cartesian Therapeutics
- CASI Pharmaceuticals
- Juventas Cell Therapy
- Novartis
- Poseida Therapeutics
- Shanghai Unicar-Therapy Bio-medicine Technology
- JW Therapeutics
- Gilead Sciences
- Cellular Biomedicine Group
- Gracell Bio
- Mustang Bio
- Servier
- iCell Gene Therapeutics
- Kecellitics Biotech Company Ltd
- Gilead sciences
- Miltenyi Biotec
- Nanjing KAEDI Biotech
- Liminatus Pharma
- Yake Biotechnology
- AffyImmune Therapeutics
- Fundamenta Therapeutics
- Actinium Pharmaceuticals
- Allogene Therapeutics
- Celyad Oncology
- Maxcyte
- Sorrento Therapeutics
- Cellular Biomedicine Group
- Sorrento Therapeutics
- Shanghai GeneChem Co., Ltd.
- Sensei Biotherapeutics
- Obsidian Therapeutics
- Beijing Biohealthcare Biotechnology Co. Ltd.
- Eutilex/Utilities
- Precigen, Inc.
- Miltenyi Biomedicine
- Wugen
- WindMIL Therapeutics
- MiNK Therapeutics
- CiMaas
- Catamaran Bio
- Innate Pharma
- Healios
- Chimeric Therapeutics
- ONK Therapeutics
- Neukio Biotherapeutics
- Exacis Biotherapeutics
- Editas Medicine
For more information about this report visit https://www.researchandmarkets.com/r/12s2go
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
